Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
Total Current Liabilities
Ascendis Pharma A/S
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Liabilities
€1.1B
|
CAGR 3-Years
84%
|
CAGR 5-Years
83%
|
CAGR 10-Years
57%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Liabilities
kr1.4B
|
CAGR 3-Years
76%
|
CAGR 5-Years
47%
|
CAGR 10-Years
37%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Liabilities
kr665m
|
CAGR 3-Years
50%
|
CAGR 5-Years
13%
|
CAGR 10-Years
25%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Current Liabilities
$1.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Liabilities
kr1.8B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Total Current Liabilities
kr44.6m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
25%
|
|
Ascendis Pharma A/S
Glance View
Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.
See Also
What is Ascendis Pharma A/S's Total Current Liabilities?
Total Current Liabilities
1.1B
EUR
Based on the financial report for Dec 31, 2025, Ascendis Pharma A/S's Total Current Liabilities amounts to 1.1B EUR.
What is Ascendis Pharma A/S's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
57%
Over the last year, the Total Current Liabilities growth was 18%. The average annual Total Current Liabilities growth rates for Ascendis Pharma A/S have been 84% over the past three years , 83% over the past five years , and 57% over the past ten years .
